Abstract
To date, there is a limited amount of literature that describes the dental quality of life measures on the OHIP-49-RU scale in patients with a confirmed diagnosis of SARS-CoV-2. Therefore, this topic is relevant. Thus, the aim of this study was to study the dental quality of life indicators according to the OHIP-49-RU scale in patients with a confirmed diagnosis of SARS-CoV-2 of moderate severity, with concomitant oral co-infection.
 Materials and methods: a comparative analysis of quality of life indicators according to the OHIP-49-RU scale was carried out in patients with a confirmed diagnosis of SARS-CoV-2. The conclusions are drawn based on the results of the survey, in which a comparative assessment of quality of life indicators on the OHIP-49-RU scale was carried out in 90 patients aged 45 to 60 years with moderate Sars-CoV-2 with oral co-infection.
 Results. During the study, the following results were obtained. An analysis of the effectiveness of the use of therapeutic and prophylactic agents in patients with SARS-CoV-2 showed that the use of a 0.05% solution of chlorhexidine bigluconate in patients with Sars-CoV-2 with concomitant oral co-infection has a more pronounced antimicrobial effect, which helps to reduce the intensity of inflammatory process in the oral mucosa and periodontal tissues, improving the quality of life than with the use of Miramistin and Rotokan.
 Findings. The data of the conducted study will constitute an important stage for improving the quality of life in patients with SARS-CoV-2.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
